Bari Interesting: Incyte, Lilly JAK Up Phase III Program
By Randy Osborne
Thursday, November 15, 2012
The recent approval of Pfizer Inc.'s Janus kinase (JAK) inhibitor tofacitinib, branded Xeljanz, for moderate to severe rheumatoid arthritis (RA) has investors salivating over the prospects for baricitinib, the drug in the same class for the same indication from Incyte Corp. and partner Eli Lilly and Co., entering Phase III trials.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.